Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors.

The role of the 5-HT(2C) receptor in mediating active behaviors in the modified rat forced swim test was examined. Three novel selective 5-HT(2C) receptor agonists, WAY 161503 (0.1-3.0 mg/kg), RO 60-0175 (2-20 mg/kg), and RO 60-0332 (20 mg/kg), all decreased immobility and increased swimming, a pattern of behavior similar to that which occurs with the selective serotonin reuptake inhibitor fluoxetine (5-20 mg/kg). However, the prototypical but nonselective 5-HT(2C) receptor agonist m-chlorophenylpiperazine (1-10 mg/kg) increased immobility scores in the forced swim test. The selective 5-HT(2C) receptor antagonist SB 206533 was inactive when given alone (1-20 mg/kg). However, SB 206533 (20 mg/kg) blocked the antidepressant-like effects of both WAY 161503 (1 mg/kg) and fluoxetine (20 mg/kg). The atypical antidepressant (noradrenergic alpha(2) and 5-HT(2C) receptor antagonist) mianserin reduced immobility and increased climbing at 30 mg/kg. At a behaviorally subactive dose (10 mg/kg), mianserin abolished the effects of WAY 161503 (1 mg/kg) on both swimming and immobility scores. Mianserin blocked the effects of fluoxetine (20 mg/kg) on swimming only; mianserin plus fluoxetine reduced immobility and induced a switch to climbing behavior, suggesting activation of noradrenergic transmission. These data exemplify the benefits of using the modified rat forced swim test, which was sensitive to serotonergic compounds and distinguished behavioral changes associated with serotonergic and noradrenergic effects. Taken together, the results strongly implicate a role for 5-HT(2C) receptors in the behavioral effects of antidepressant drugs.

[1]  H. Berendsen,et al.  Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? , 1995, Pharmacology & therapeutics.

[2]  W. Haefely,et al.  Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. , 1993, European journal of pharmacology.

[3]  V. Mutel,et al.  Brain 5-HT1C receptors and antidepressants , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  I. Lucki.  Behavioral studies of serotonin receptor agonists as antidepressant drugs. , 1991, The Journal of clinical psychiatry.

[5]  I. Lucki,et al.  Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test , 1998, Psychopharmacology.

[6]  F. Borsini,et al.  Mesulergine antagonism towards the fluoxetine anti‐immobility effect in the forced swimming test in mice , 1993, The Journal of pharmacy and pharmacology.

[7]  M. Millan,et al.  Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. , 1997, Journal of neurochemistry.

[8]  I. Lucki,et al.  Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.

[9]  I. Forbes,et al.  In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British journal of pharmacology.

[10]  B. Leonard,et al.  5‐HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response , 2000, Human psychopharmacology.

[11]  L. Cervo,et al.  1-(3-Trifluoromethylphenyl) piperazine (TFMPP) in the ventral tegmental area reduces the effect of desipramine in the forced swimming test in rats: possible role of serotonin receptors. , 1989, European journal of pharmacology.

[12]  F. Blaney,et al.  5-HT2 receptor subtypes: a family re-united? , 1995, Trends in pharmacological sciences.

[13]  L. D. van de Kar,et al.  Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI). , 1993, The Journal of pharmacology and experimental therapeutics.

[14]  I. Lucki,et al.  The spectrum of behaviors influenced by serotonin , 1998, Biological Psychiatry.

[15]  M. Bös,et al.  5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats , 1996, European Neuropsychopharmacology.

[16]  D. Murphy,et al.  Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. , 1991, Pharmacological reviews.

[17]  M. Hamon,et al.  Anpirtoline, a novel, highly potent 5‐HT1B receptor agonist with antinociceptive/antidepressant‐like actions in rodents , 1992, British journal of pharmacology.

[18]  H. Meltzer,et al.  Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. , 1999, Journal of clinical psychopharmacology.

[19]  J. Palacios,et al.  The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution , 1990, Neuroscience.

[20]  P. Goodnick,et al.  Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology , 1998, Journal of psychopharmacology.

[21]  A. Sleight,et al.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[22]  S. Lightowler,et al.  Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT 2C 2B receptor function , 1994, Neuropharmacology.

[23]  A. Gobert,et al.  α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats , 1997 .

[24]  I. Lucki.  The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. , 1997, Behavioural pharmacology.

[25]  Trevor R. Norman,et al.  Behavioral studies of serotonin receptor agonists as antidepressant drugs. , 1991 .

[26]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[27]  H. Berendsen,et al.  Drug-induced penile erections in rats: indications of serotonin1B receptor mediation. , 1987, European journal of pharmacology.

[28]  F. Hoffmann-La.  5-HT 2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential , 1998 .

[29]  M. Detke,et al.  Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. , 1997, Experimental and clinical psychopharmacology.

[30]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[31]  J. Palacios,et al.  The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. , 1984, European journal of pharmacology.

[32]  H. Berendsen,et al.  Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure. , 1994, European journal of pharmacology.

[33]  M. Reith,et al.  Extracellular Dopamine, Norepinephrine, and Serotonin in the Nucleus Accumbens of Freely Moving Rats During Intracerebral Dialysis with Cocaine and Other Monoamine Uptake Blockers , 1996, Journal of neurochemistry.

[34]  P. Cowen,et al.  SSRI treatment decreases prolactin and hyperthermic responses to mCPP , 1997, Psychopharmacology.

[35]  F. Borsini,et al.  Evidence that imipramine activates 5-HT1C receptor function. , 1991, European journal of pharmacology.